Program
Atrasentan
Also written as “Drug: Atrasentan”, “atrasentan” and “0.25 mg Atrasentan QD”.
Its studies are mostly in Glomerulonephritis, IGA · Prostatic Neoplasms · Renal Insufficiency, Chronic · Kidney Diseases · Diabetic Nephropathies, led by 3 companies.
Drug pageAtrasentan: every studyAll 21 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbott | 50 open or running | phase 3since May 10, 2002 | May 10, 2002 | none ahead |
| AbbVieits history only | 50 open or running | phase 3since May 17, 2013 | Jun 11, 2009 | none ahead |
| Novartisits history only | 54 open or running | phase 3since Sep 12, 2020 | Sep 12, 2020 | Apr 14, 2028phase 3 · NCT04573478 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Abbott only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 10, 2002First studies: 2 phase 3 studies in Prostatic NeoplasmsFirst studyNCT00036556, NCT00036543
- Jun 3, 2002Phase 2 study in Prostatic NeoplasmsNCT00038662 · 200 enrolled · United States, Canada
- Oct 3, 2002Phase 3 study in Prostatic NeoplasmsNCT00046943 · United States
- Aug 4, 2005Phase 3 study in Prostatic NeoplasmsNCT00127478 · 166 enrolled · United States, Canada, France and more
TargetBeta
“Endothelin receptor ET-A antagonist”ChEMBL 37, by rule
Other programs on EDNRA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bosentanrule | Johnson & Johnson | phase 4 | 37 |
| sparsentanrule | travere-therapeutics-inc | phase 4 | 9 |
| zibotentan | AstraZeneca | phase 3 | 23 |
| aprocitentanrule | Idorsia Pharmaceuticals | phase 3 | 14 |
Studies
All 5 Abbott leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00127478Prostatic Neoplasms · United States, Canada, France and more | 3 | Completed | 166 | |
| NCT00046943Prostatic Neoplasms · United States | 3 | Completed | Jun 2007 | |
| NCT00038662Prostatic Neoplasms · United States, Canada | 2 | Completed | 200 | |
| NCT00036556Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | 941 | |
| NCT00036543Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | 1,000 |
How it is read
Names in the registry
- “Atrasentan”, 12 entries
- “Drug: Atrasentan”, 1 entry
- “atrasentan”, 1 entry
- “0.25 mg Atrasentan QD”, 1 entry
- “0.75 mg Atrasentan QD”, 1 entry
Conditions, from the studies’ own filings
- Glomerulonephritis, IGA, 5 studies
- Prostatic Neoplasms, 5 studies
- Renal Insufficiency, Chronic, 3 studies
- Kidney Diseases, 1 study
- Diabetic Nephropathies, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.